Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Target identification of CQ31, a selective activator of the CARD8 inflammasome

ABSTRACT: Target identification of CQ31 using the photoreactive diazirine-alkyne probe, CQ73.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Andrew Griswold

LAB HEAD: Daniel Bachovchin

PROVIDER: PXD027707 | Pride | 2021-11-17

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	1814QC_S1_TMT1_i39_DBachovchin.raw	Raw
	1814QC_S1_TMT2_i39_DBachovchin.raw	Raw
	allPeptides.txt	Txt
	checksum.txt	Txt
	evidence.txt	Txt

Items per page:

1 - 5 of 9

Similar Datasets

Target identification of methyl bestatin

Project description:Target identification of methyl bestatin (MeBs) using the photoreactive diazirine-alkyne probe, CQ83.

2022-11-22 | PXD038233 | Pride

Proteome-wide profiling of olaparib interactors using a biotinylated photoaffinity probe

Project description:Olaparib is a widely used PARP inhibitor for the treatment of BRCA-mutated cancers. To comprehensively understand the drug's clinical impact, measuring its interactions with intended on- and off-targets is crucial. In this study, olaparib's on- and off-targets were profiled using photoaffinity labeling, a powerful, proteome-wide method for studying the direct interactions between a drug and its protein targets. A novel photoaffinity probe was designed and used in a proteomic screening to discover novel targets of olaparib in the human proteome. The probe, incorporating a pre-installed biotin group, bypasses the limitations of using a copper(I)-catalyzed click reaction in cell lysates for reporter group conjugation and revealed a broad range of olaparib interactors, including previously unreported proteins, in a quantitative mass spectrometry-based proteomic screening using HeLa whole cell lysate. The study contributes to our current understanding of the pharmacology of olaparib and provides a valuable tool for elucidating drug interactors within cell lysates, potentially guiding the development of more targeted therapeutics with fewer off-targets.

2025-02-04 | PXD060372 | Pride

RNA-Seq of A375 cells treated with tetracycline-based crosslinking probes, with and without competition by parent tetracyclines, to show specific binding of the tetracycline analogs Col-3 and doxycycline on rRNA substructures of the human ribosome

Project description:Upon finding that the tetracyclines COL-3 and doxycycline target unique rRNA substructures of the 80S ribosome (E-MTAB-7147), we confirmed these putative ribosomal binding sites by showing that tetracycline-based crosslinking probes are specifically competed from these rRNA structures by their parent drugs. In short, we incorporated dual bioorthogonal handles into tetracycline-based probes, containing both a photoactive diazirine to enable direct probe crosslinking to the human ribosome and an azide handle to allow selective enrichment of crosslinked biomolecules via copper-free ‘click’ chemistry. The COL-3 and doxycycline probes were each incubated with A375 cells, followed by irradiation at 365 nm to induce photolysis of the diazirine moiety and subsequent crosslinking to adjacent ribosomal components. Pulldown and RNA-Seq of the crosslinked RNAs from our experiments were used to identify enrichment of reverse transcription (RT) stops at ribosomal RNA sites caused by local crosslinking of our probes. In these experiments, UV crosslinking was preformed with the COL-3 and doxycycline probe compounds in the presence and absence of free COL-3 and doxycycline (i.e., parent tetracycline molecules lacking the bifunctional diazirine-azide moiety), which were used as competitors to specifically diminish crosslinking to the ribosomal RNA. Crosslinking to ribosomal RNA was determined using RNA-Seq based RT stop enrichment, which was was also compared to inactive tetracycline probes containing a modified bifunctional linker, a non-specific aniline probe, and untreated controls.

2018-08-31 | E-MTAB-7161 | biostudies-arrayexpress

A Bacteroides fragilis protease activates host PAR2 to induce intestinal pain and inflammation

Project description:Protease-activated receptor 2 (PAR2) is a central regulator of intestinal barrier function, inflammation and pain. Upregulated intestinal proteolysis and PAR2-signaling are implicated in inflammatory bowel diseases (IBDs) and irritable bowel syndrome (IBS), conditions often associated with gut microbiome alterations. To identify potential bacterial regulators of PAR2 activity, we developed a functional assay for PAR2 processing and screened a library of diverse gut microbes. We found that multiple bacteria secrete proteases that cleave host PAR2. Using chemoproteomic profiling with a covalent irreversible inhibitor, we uncovered a previously uncharacterized Bacteroides fragilis serine protease 1 (Bfp1) and show that it cleaves and activates PAR2 in multicellular and murine models. PAR2 cleavage by Bfp1 disrupts the intestinal barrier, sensitizes nociceptors, and triggers colonic inflammation and abdominal pain. Collectively, our findings uncover Bfp1-mediated PAR2-processing as a new axis of host-commensal-interaction in the gut that has the potential to be targeted for therapeutic intervention in IBD or IBS.

2025-09-28 | PXD059166 | Pride

Sulfoxide-diazirine (SODA) as a cleavable photoaffinity group to enable identification of photolabeled modification sites via LC-MS3

Project description:Photoaffinity labeling is a common approach in chemical proteomics for identification of small molecule probe tar-gets. However, the modification site on the target protein remains difficult to identify, because of the probe modifica-tion and potential fragmentation during tandem mass spectrometry. We here introduce MS-cleavable photoaffinity groups for a better identification of the modification site. These are based on diazirine photoreactive groups and sul-foxide as MS-labile linker. We have applied these in photoaffinity probes based on the peptide-like aspartic protease inhibitor pepstatin A, and we demonstrate that we can identify and map binding hotspots on structural models of a target protease.

2025-08-25 | PXD065837 | Pride

Olaparib based photo-affinity probes for PARP-1 detection in living cells

Project description:The poly-ADP-ribose polymerase (PARP) is a protein from the family of ADP-ribosyltransferases that catalyzes poly adenosine diphosphate ribose (ADPR) formation in order to attract the DNA repair machinery to DNA damage sites. Inhibition of PARP activity by olaparib can cause cell death which is of clinical relevance in some tumor types. This demonstrates that quantification of PARP activity in the context of living cells is of great importance. In this work we present the design, synthesis and biological evaluation of photo-activatable affinity probes inspired by the olaparib molecule which are equipped with a diazirine for covalent attachment upon activation by UV light and a ligation handle for the addition of a reporter group of choice. SDS-PAGE, western blotting and label-free LC-MS/MS quantification analysis show that the probes target the PARP-1 protein and are selectively outcompeted by olaparib suggesting binding in the same enzymatic pocket.

2020-04-29 | PXD018661 | Pride

BSA,HSA,myoglobin,mouse liver LC-MS/MS

Project description:We systematically explored the VUV photochemical reactions of aqueous halides Cl−, Br−, and I− with native proteins and peptides under the irradiation of a 10-ns single pulse of 193-nm ArF VUV laser

2022-08-15 | PXD024795 | Pride

Chemical tools to expand the ligandable proteome: elaborated fragment-based photoreactive stereoprobes

Project description:Efforts to expand the ligandable proteome have explored stereochemically defined fragments equipped with photoreactive and clickable handles (photo-stereoprobes) for mapping reversible small molecule-protein interactions in living systems. Here, we investigate the impact of structural elaboration of fragment photo-stereoprobes on interactions with the proteome of human cancer cells. We find that even conservative increases in size and complexity have profound effects on protein binding for fragment photo-stereoprobes, leading to enhanced stereoselective protein interactions, while abrogating others. We use stereochemically matched competitor ligands to assess the extent of protein binding in human cells, leading to the discovery of high-stoichiometry ligands for proteins from different functional classes, including a structurally novel set of epoxide hydrolase inhibitors. Our findings support the broad ligandability potential of the human proteome while also highlighting challenges in converting reversible small molecule-protein interaction maps into more advanced chemical probes.

2024-05-31 | PXD052692 | Pride

AP-MS of small molecule that selectively destabilizes Cryptochrome 1

Project description:Cryptochromes are negative transcriptional regulators of the circadian clock in mammals. It is not clear how reducing the level of endogenous CRY1 in mammals will affect circadian rhythm and the relation of such a decrease with apoptosis. Here, we discovered a molecule (M47) that destabilizes Cryptochrome 1 (CRY1) both in vitro and in vivo. The M47 selectively enhanced the degradation rate of CRY1 by increasing its ubiquitination and resulted in increasing the circadian period length of U2OS Bmal1-dLuc cells. In addition, subcellular fractionation studies from mice liver indicated that M47 increased degradation of the CRY1 in the nucleus. Furthermore, M47-mediated CRY1 reduction enhanced cisplatin-induced apoptosis in Ras-transformed p53 null fibroblast cells. Systemic repetitive administration of M47 increased the median lifespan of p53-/- mice by ~25%. Collectively our data suggest that M47 is a very promising molecule to treat forms of cancer depending on the p53 mutation.

2022-11-07 | PXD037311 | Pride

Chemical proteomics of AP-3 in Actinosynnema pretiosum

Project description:we use chemoproteomic approach with an AP-3-derived photoaffinity probe to profile the proteome-wide interactions of AP-3.

2023-10-24 | PXD043867 | Pride